SIT PHARMA is pleased to announce the acquisition of OSTIDIL-D3 and KEFORAL
SIT Pharma is pleased to announce the acquisition of DERINOX® from Therabel Lucien Pharma Sas
SIT Pharma is pleased to announce the acquisition of MIZOLLEN® from THERABEL HEALTHCARE LIMITED
SIT Pharma was mentioned by the prestigious business publication “Il Sole 24 Ore” in its 18 April 2025 edition, in a space dedicated to outstanding companies in the Pavia area.
SIT Pharma is pleased to announce the acquisition of DINTOINA brand.
The product is indicated for generalized epilepsy control, excluding petit mal and partial seizures.
On this occasion, together with students and teachers, we played on the themes of peace, inclusion and active citizenship.
The European Business magazine interviewed Lamberto Pedrotti, Managing Director of SIT Group.
The Ambient Marketing Fomentil has begun in Turin, Milan e Pavia.
The advertising campaign of Rino Calyptol will be live in April.
#sostenGO is an initiative to support female entrepreneurship, promoted by SIT Group since 2017.
The advertising campaign of Rino Calyptol returns live in December.
Laboratorio Farmaceutico SIT is pleased to announce the release of the new Coryfin C senza zuccheri Miele e Zenzero.
Laboratorio Farmaceutico SIT strengthens the relationship between Company and Doctor, with the implementation of its own network of medical representatives.
Trofodermin Spray has been on the market again since April 2020.
SIT Group is pleased to announce the acquisition of LOPRESSOR, ICAZ and MIOREL from Daiichi Sankyo France, effective from 30th June 2020.
Laboratorio Farmaceutico SIT is pleased to announce the release of the new Coryfin C senza zuccheri Miele e Zenzero.
The new Trofodermin TV spot is now on air.
SIT Group is pleased to announce the acquisition of Natifar and Natimed brands from Laboratorios BIAL, a Spanish affiliate of BIAL Group (BIAL), as a result of the agreement signed on October 25th, 2022.
SIT Group is pleased to announce the acquisition of established product SULMETIN from Sanofi, as a result of the agreement signed on November 8, 2022.
SIT Group is pleased to announce the acquisition of established product SULMETIN from Sanofi, as a result of the agreement signed on November 8, 2022.
The entire line of Centellase is illustrated on the new website, including the new product Centellase Cell Filler contorno occhi.